Christopher James Stevens, an officer of Rocket Pharmaceuticals, Inc., filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 16,131 shares of common stock on NASDAQ under Rule 144 of the Securities Act of 1933.

Key Highlights

  • Proposed sale: 16,131 shares of Rocket Pharmaceuticals common stock, with an aggregate market value of $37,530.38, according to the filing.
  • Acquisition source: The shares were acquired through restricted stock vesting from the issuer on November 4, 2026, as compensation.
  • Approximate sale date: November 9, 2026, through Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917.
  • Shares outstanding: The filing states 109,774,597 shares of common stock were outstanding at the time of the notice.
  • Prior sales: The filing discloses a prior sale of 36,658 shares on August 11, 2026, with gross proceeds of $128,281.01.
  • Tax-related purpose: According to the filing, the "sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."

Stevens Proposes Sale of Vested Restricted Stock at Rocket Pharmaceuticals

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Christopher James Stevens, identified as an officer of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), intends to sell 16,131 shares of the company's common stock. The filing lists an aggregate market value of $37,530.38 for the proposed sale, with Fidelity Brokerage Services LLC named as the executing broker. The approximate date of sale is listed as November 9, 2026.

The filing discloses that the 16,131 shares were acquired on November 4, 2026, through a restricted stock vesting transaction from the issuer, with payment characterized as compensation. The filing notes the sale is intended, at least in part, to cover a tax obligation arising from the vested equity award distribution, quoting the remarks section directly: "Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."

In the section covering securities sold during the prior three months, the filing reports that Stevens sold 36,658 shares of common stock on August 11, 2026, generating gross proceeds of $128,281.01. The total shares of Rocket Pharmaceuticals common stock outstanding is listed in the filing as 109,774,597. The notice was signed by Jennifer Ruchti as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Stevens.

What Was Disclosed

A Form 144 notice filed November 9, 2026, discloses Rocket Pharmaceuticals officer Christopher James Stevens's proposed sale of 16,131 shares of common stock acquired via restricted stock vesting, with a stated aggregate market value of $37,530.38, partly to cover tax obligations from the vesting event.